Zenas BioPharma (ZBIO) Operating Leases (2023 - 2026)

Zenas BioPharma's Operating Leases history runs 4 years deep, the most recent figure standing at $77000.0 for Q1 2026.

• On a quarterly basis, Operating Leases fell 75.71% year-over-year to $77000.0 in Q1 2026; TTM through Mar 2026 was $77000.0, a 75.71% decrease from a year earlier, with the FY2025 full-year figure at $211000.0, down 3.21% from the prior year.
• Operating Leases eased to $77000.0 in Q1 2026 per ZBIO's latest filing, from $211000.0 in the prior quarter.
• Across five years, Operating Leases topped out at $317000.0 in Q1 2025 and bottomed at $77000.0 in Q1 2026.
• The 4-year median for Operating Leases is $215000.0 (2025), against an average of $210714.3.
• Across the five-year window, Operating Leases slipped 3.21% in 2025 and sank 75.71% in 2026, its largest moves.
• Year by year, Operating Leases stood at $257000.0 in 2023, then fell by 15.18% to $218000.0 in 2024, then decreased by 3.21% to $211000.0 in 2025, then plunged by 63.51% to $77000.0 in 2026.
• Per Business Quant, the three latest ZBIO Operating Leases figures stand at $77000.0 (Q1 2026), $211000.0 (Q4 2025), and $180000.0 (Q3 2025).